NCT01458704

Brief Summary

Next generation sequencing (including targeted gene seqeuncing, exome and transcriptome sequencing) will be performed from fresh frozen tumor samples to understand the genetic alteration of tumors and to aid in optimal selection of further therapeutic agents.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2011

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

October 23, 2011

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 25, 2011

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2013

Completed
Last Updated

October 25, 2011

Status Verified

October 1, 2011

Enrollment Period

1.7 years

First QC Date

October 23, 2011

Last Update Submit

October 24, 2011

Conditions

Outcome Measures

Primary Outcomes (1)

  • targeted sequencing of cancer-relate genes

    Identification and characterization of genetic alteration in cancer tissue

    1 year

Study Arms (1)

fresh frozen tumor tissue

patients providing fresh frozen tumor tissue

Other: next generation sequencing

Interventions

next generation sequencing (including targeted gene sequencing, exome sequencing, transcriptome sequenicing)

fresh frozen tumor tissue

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients with malignant tumor receiving or planning to receive chemotherapy with fresh frozen tumor tissue with informed consent

You may qualify if:

  • patients with malignant tumor
  • receiving or planning to receive chemotherapy
  • with fresh frozen tumor tissue
  • with informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Seoul National University Hospital

Seoul, 110-744, South Korea

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

fresh frozen tumor tissue

MeSH Terms

Conditions

Neoplasms

Interventions

High-Throughput Nucleotide Sequencing

Intervention Hierarchy (Ancestors)

Sequence AnalysisGenetic TechniquesInvestigative Techniques

Study Officials

  • Tae-You Kim

    Seoul National University Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Tae-You Kim

CONTACT

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 23, 2011

First Posted

October 25, 2011

Study Start

August 1, 2011

Primary Completion

April 1, 2013

Last Updated

October 25, 2011

Record last verified: 2011-10

Locations